NASDAQ · ANGN
Angion Biomedica Corp.
$1.00$0.00 (0.0%)
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
Loading market information…
NASDAQ · GMTX · USD
Stock price, earnings
Quote as of Dec 30, 2022, 05:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Gemini Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gemini Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1.00$0.00 (0.0%)
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
$1.99+$0.10 (+5.29%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.2% below the high.
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$8.50+$0.01 (+0.12%)
Liminal BioSciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$4.30-$0.14 (-3.15%)
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
